Quality & complianceOfficial

Denmark flags supply problems for Zyprexa 10 mg powder for injection from 2care4

🇩🇰 DKMA · Mon 26 Oct 2026

The Danish Medicines Agency reports delivery difficulties affecting olanzapine injection powder, with disruption expected from early September to early November 2026.

The Danish Medicines Agency (DKMA) has published a supply notice for Zyprexa 10 mg powder for solution for injection, marketed in Denmark by 2care4 ApS. The notice is dated 26 October 2026 and says there are current problems with supply of the product.

The active substance is olanzapine (ATC code N05AH03). DKMA gives the expected period of disruption as the start of September to the start of November 2026, and names the cause as delivery difficulties. The notice does not elaborate on the nature of those difficulties.

The agency does not name alternative products or set out any measures for prescribers or pharmacies. It says questions about the current status of supply should be addressed to the company, 2care4 ApS.

The notice appears in DKMA's section for supply announcements on medicines. As context, national regulators typically publish such notices so that healthcare professionals and pharmacies can plan around temporary shortages.

What it means for your team

  • Supply and market-access teams with Danish exposure should note the stated window of early September to early November 2026, which is nearing its end according to the notice date.
  • The notice gives no cause beyond 'delivery difficulties', no alternatives and no guidance on duration beyond the stated period, so current status must be confirmed with 2care4 ApS.
  • Regulatory teams tracking shortages should log the notice, as it concerns an injectable antipsychotic presentation of olanzapine.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →